Tag Archives: mortalidad

ARA II o IECA, lo más caro no es siempre lo mejor.


Fuente: Sinestesia Digital La revisión : “The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review”afirma que el uso de ARA II solos, o en combinación con IECAs (el famoso doble bloqueo del eje renina-angiotensina) no … Continue reading

Posted in ARA, efectividad clinica, IECA, Medicamentos, mortalidad | Tagged , , , , , | Leave a comment

¿A qué se debe la reducción de la mortalidad por cardiopatía isquémica?


Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW. How Much of the Recent Decline in the Incidence of Myocardial Infarction in British Men Can Be Explained by Changes in Cardiovascular Risk Factors?: Evidence From a Prospective … Continue reading

Posted in Articulos de interés, Cardiologia | Tagged , , , , | Leave a comment

Eficacia de una intervención multifactorial sobre la diabetes para reducir la mortalidad


Eficacia de una intervención multifactorial sobre la diabetes para reducir la mortalidad Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 580-591.  R   … Continue reading

Posted in Articulos de interés, Diabetes Mellitus | Tagged , , , , | Leave a comment

Eficacia de una intervención multifactorial sobre la diabetes para reducir la mortalidad


Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 580-591.  R   TC (s)   PDF (s) Introducción La diabetes es un problema de … Continue reading

Posted in Articulos de interés, Diabetes Mellitus | Tagged , , , , , | Leave a comment

“Los efectos adversos de los fármacos son ya la primera causa de muerte en EE UU”


Fuente: Gonzalo Moyano en ALAMES ENTREVISTA / MIGUEL JARA, AUTOR DE ‘TRAFICANTES DE SALUD’ http://www.diagonalperiodico.net/article3044.html Belén Macías Marín . Redacción Contra el gigante blanco. El autor de Traficantes de salud, que salió a la venta la semana pasada, planta cara … Continue reading

Posted in Medicamentos | Tagged , , , | Leave a comment

La capacidad de ejercicio es un fuerte predictor de mortalidad


La capacidad de ejercicio predice fuertemente el riesgo de muerte en hombres, de acuerdo a un estudio publicado en CirculationCerca de 16,000 hombres se sometieron a ejercicio en una banda continua y se siguieron alrededor de 7.5 años. Después del … Continue reading

Posted in Cardiologia | Tagged , , , | Leave a comment

Gilgamesh


Autor: Juan Gervas La economía de supervivencia empezó a convertirse en una economía de producción 10.000 años antes de Cristo, casi simultáneamente en China y en el Oriente Próximo. De la recolección se pasó lentamente a la agricultura y a … Continue reading

Posted in Juan Gervas | Tagged , , , , , , , , , | Leave a comment

AP al dia: Resumenes Comentados


¿Qué fármacos son los principales responsables de las reacciones adversas a medicamentos en ancianos? HTML PPT ¿Son útiles los antibióticos y los corticoides nasales en el tratamiento de la sinusitis? HTML PPT Utilidad de una prueba de diagnóstico rápido en … Continue reading

Posted in Articulos de interés | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

AP al dia: Resumenes comentados


En adultos con faringitis estreptocócicas de repetición, la amigdalectomía es eficaz para prevenir recaídas a corto plazo HTML PPT Los pacientes con síndrome del intestino irritable tienen un mayor riesgo de ser sometidos a una apendicectomía negativa HTML PPT La … Continue reading

Posted in Articulos de interés | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003


La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003 Susan M. Hutfless Susan M. Hutfless , ‡ , Xiaoping Weng ‡ , Liyan Liu ‡ , James Allison ‡ , § and Lisa J. … Continue reading

Posted in Gastroenterologia, Medicamentos | Tagged , , , | Leave a comment

La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003


La mortalidad por el uso de fármacos en los pacientes con enfermedad inflamatoria intestinal, 1996-2003 Susan M. Hutfless Susan M. Hutfless , ‡ , Xiaoping Weng ‡ , Liyan Liu ‡ , James Allison ‡ , § and Lisa J. … Continue reading

Posted in Gastroenterologia, Medicamentos | Tagged , , , | Leave a comment

Physician's First Watch


Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Fitness Strongly Predicts Mortality Risk in the Elderly, Regardless of Adiposity FDA: Desmopressin Increases Risk for Hyponatremia Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Amoxicillin or budesonide, either alone … Continue reading

Posted in First Watch | Tagged , , , , , , , , , | 1 Comment

Physician’s First Watch


Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Fitness Strongly Predicts Mortality Risk in the Elderly, Regardless of Adiposity FDA: Desmopressin Increases Risk for Hyponatremia Antibiotic, Nasal Steroid Not Effective for Treating Acute Sinusitis Amoxicillin or budesonide, either alone … Continue reading

Posted in First Watch | Tagged , , , , , , , , , , | 1 Comment

Effects of Torcetrapib in Patients at High Risk for Coronary Events


ABSTRACT Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because … Continue reading

Posted in Efectos Adversos, Medicamentos | Tagged , , , , , | Leave a comment

Cambio en la formula del Yectafer


Las inyecciones de hierro Yectafer, utilizadas habitualmente en el tratamiento de las anemias, cambiaron su formulación, modificando uno de los componentes, según anunciaron las autoridades del laboratorio que las produce. Según señalaron en una conferencia de prensa los responsables en … Continue reading

Posted in hierro, Yectafer | Tagged , , , , , , , , , , , | 2 Comments

Leptospirosis en Republica Dominicana


INFECCIÓN RELACIONADA CON LAS LLUVIAS 26 muertos por un brote de leptospirosis en la República Dominicana Fuente: El Mundo.es Actualizado martes 20/11/2007 11:50 SANTO DOMINGO.- Al menos 26 personas murieron por un brote de leptospirosis tras el paso de la … Continue reading

Posted in Infectologia, Medio Ambiente, Noticias | Tagged , , , , , , , | 2 Comments

AP al dia: resumenes comentados


¿El cribado del VPH es eficaz para la prevención del cáncer de cérvix? HTML PPT Prevalencia de la enfermedad renal crónica en EEUU HTML PPT Relación entre el IMC y la causa de muerte HTML PPT Hallazgos incidentales en las … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , | Leave a comment

Recorriendo (un poco) la blogosfera medica


El supositorio: Breve, conciso, preciso, que más pedirle a un blog con dos posts de gran calidad. La promoción de los medicamentos en los países en vías de desarrollo Raloxifeno: incremento del riesgo de mortalidad por ictus Primum Non Nocere … Continue reading

Posted in Blogosfera | Tagged , , , , , , , , , , , | Leave a comment

Pediatria Basada en la Evidencia


Adolescentes y drogas. Un reto para los profesionales sanitarios Hidalgo Vicario MI, Redondo Romero A. Evid Pediatr. 2007;3:60. [HTM] [PDF] Papel protector de la lactancia materna en las infecciones de la infancia: análisis crítico de la metodología de estudio Paricio … Continue reading

Posted in Medicina Basada en la Evidencia, Salud en Adolescentes, Salud Infantil | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

El sobrepreso disminuye la mortalidad: l@s gordit@s festejan


Hace alrededor de dos años, un equipo de científicos estatales informó que las personas con sobrepeso tienen una tasa de mortalidad más baja que las personas con peso normal, bajo peso u obesas. Ahora, después de seguir investigando, el mismo … Continue reading

Posted in mortalidad, Sobrepeso | Tagged , , , , | Leave a comment

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading

Posted in Asma, Medicamentos, mortalidad, Salud Infantil | Tagged , , , , | Leave a comment

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading

Posted in Asma, Medicamentos, mortalidad, Salud Infantil | Tagged , , , , , | Leave a comment

Journal Watch en Portugues


Diagnóstico de incontinência urinária com três perguntas Biópsia de nódulo sentinela = menos linfedema e melhor qualidade de vida (ALMANAC) Ondansentrona é efetiva para gastroenterite com vômitos Acupressão tem melhor desempenho que fisioterapia para lombalgia Ressonância não é precisa no … Continue reading

Posted in Journal Watch, WONCA | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

AP al dia: resúmenes comentados


El tratamiento de la obesidad importante mediante cirugía bariátrica se asocia a una menor mortalidad HTML PPT ¿Es eficaz el cribado de la fibrilación auricular en atención primaria? HTML PPT Relación entre el consumo habitual de Cannabis y el desarrollo … Continue reading

Posted in Articulos de interés | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Suspension de comercializacion de aprotinina


La FDA anuncio que ante un pedido de la agencia, Bayer Pharmaceuticals Corp. accedio  a la suspension de la  comercializacion de aprotinina, a la espera de una evaluacion mas detallada de los resultados preliminares del ensayo clinico canadiense BART, llevado … Continue reading

Posted in Medicamentos, mortalidad | Tagged , , , , , , , , | Leave a comment

Cirugía de bypass gástrico asociada con disminución de mortalidad cardiovascular


Cirugía de bypass gástrico asociada con disminución de mortalidad cardiovascular El bypass gástrico es el procedimiento de cirugía bariátrica más frecuente en USA. Estos autores siguieron a 7925 pacientes sometidos a procedimientos de bypass gástrico y los aparejaron por edad, … Continue reading

Posted in obesidad, WONCA | Tagged , , , , , , | Leave a comment

AP al dia: Resumenes comentados


¿Cuáles son los principales factores relacionados con la mortalidad en mujeres? HTML PPT La incidencia de los AVC tiende a disminuir en las últimas décadas HTML PPT El consumo moderado de alcohol se asocia a una reducción del 20% de … Continue reading

Posted in Articulos de interés | Tagged , , , , , , , , , , | Leave a comment